Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Orphan Drug 2022 Report
Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of drug development—outpacing the growth of the wider pharmaceuticals landscape, and accounting for an increasingly large proportion of novel drugs hitting the market. By 2026, orphans…
Report library
Genetic Medicine: The Next Generation
Huge investment in the first generation of genetic medicine led, by and large, to incredibly high valuations for companies, and before too long, some in the market began…
Orphan Drug 2022 Infographic
In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it…
PD(L)anner - March 2022
The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing…
Vantage 2021 Review Report
Once again, our award-winning, independent editorial team provides thought-provoking insights into the business development decisions and financing deals that shaped the…
Vantage 2021 Review Infographic
Bringing you a snapshot of the critical themes from Evaluate Vantage’s 2021 in Review, this infographic touches on key business development decisions and financing deals…
JP Morgan 2022 Conference
Evaluate Vantage provided comprehensive coverage of the 40th Annual J.P. Morgan Health Care Conference, held virtually from 10 to 13 January. This article pack rounds…
PD(L)anner - December 2021
In this special report, we provide you with the latest Evaluate Vantage update on clinical and regulatory developments in the PD-(L)1 inhibitor space. Among other issues,…
ASH 2022 Conference Round Up
This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual…
Investor Interviews: Evaluate Vantage 2022 Preview
After a bruising 2021, biotech investors are hoping for a rebound. We interviewed investors and biopharma participants from across the sector, asking them to share their…
Infographic: Evaluate Vantage 2022 Preview
Leading up to the publication of the Evaluate Vantage 2022 Preview, we created this Infographic to provide a snapshot of the products and companies that are driving top…
